An interventional study of TargEted MAnageMent Intervention (TEAM) in Stroke and Transient Ischemic Attack, sponsored by Case Western Reserve University. Completed at 1 site in United States. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Case Western Reserve University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 293rd largest by enrollment of the 1,621 interventional ones that give a count, is one of 88 that started in 2020, is one of 1,124 with no phase, and was the 1,284th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 90 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 88 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,332 that completed or were terminated, 564 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
Case Western Reserve University is the lead sponsor of 160 studies on the registry; 28 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.
Case Western Reserve University has 7 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
167 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 167 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs. wait-list (WL, N=80) control in African American men who have experienced a stroke or TIA within the past 5 years.
The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs. wait-list (WL, N=80) control in African American men who have experienced a stroke or TIA within the past 5 years. TEAM features a nurse-led, person-centered, holistic intervention that takes advantage of existing strengths in AA families/communities. TEAM uses peer educator dyads (PEDs) to provide support and model behaviors. The PED consists of an AA man peer educator (PE) with experience in managing his own stroke risk and a care partner. A care partner is someone who is the family member, friend or other individual of someone who has had a stroke or TIA. A care partner can be associated with a PE but they do not have to be. PEs and care partners will be matched depending on schedules and availability and may not always be members of the same household. The nurse and PED co-deliver TEAM to an AA male patient who has experienced stroke or TIA. Patients are also encouraged to include a family, friend, or other individual important his stroke recovery in the TEAM programming. The intervention is a practical approach suitable for implementation in specialty, primary care or community settings, and has the potential to reverse the unacceptably high morbidity seen in AA men due to stroke-related disorders.
Inclusion Criteria for RCT participant:
Inclusion Criteria for Care Partner
Inclusion criteria for peer educator:
Inclusion Criteria for Peer Educator Care Partner
Exclusion Criteria for RCT participant
Exclusion Criteria for Care Partner participant 1. Individuals who are unable or unwilling to provide written informed consent
Exclusion Criteria for Peer Educator
Exclusion Criteria for Peer Educator's Care Partner
1. Individuals who are unable or unwilling to provide written informed consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
Behavioral: TargEted MAnageMent Intervention (TEAM)
Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
Behavioral: TargEted MAnageMent Intervention (TEAM)
TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows: 1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning. 2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED. 3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers.
TEAM vs WL Systolic BP
BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.
Time frame: Baseline, Month 3, Month 6
TEAM vs WL Diastolic BP
BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.
Time frame: Baseline, Month 3, Month 6
TEAM vs WL Cholesterol
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL HDL
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL LDL
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL Triglycerides
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL BMI
Height was measured at baseline and weight was measured at baseline and at 6-month follow-up timepoints. If individuals were unable to provide accurate height and weight measurements, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL HbA1c
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
Time frame: Baseline, Month 6
TEAM vs WL Stroke Knowledge Test (SKT)
The SKT is a 20-item multiple-choice test designed to measure knowledge and understanding of stroke, stroke risk, stroke risk factors, and stroke prevention practices. In this study, only five specific questions were asked to examine each participant's knowledge of specific stroke risk factors and stroke prevention practices. Possible scores range for 0-5, with a higher score indicating a higher amount of knowledge and understanding
Time frame: Baseline, Month 3, Month 6
TEAM vs WL General Self-Efficacy Scale (GSE)
The GSE a 10-item psychological questionnaire designed to measure an individual's optimistic self-belief in their ability to handle difficult demands, cope with stress, and overcome obstacles. Total scores range from 10 to 40, where higher scores mean a stronger general sense of self-efficacy
Time frame: Baseline, Month 3, Month 6
TEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)
The MOS-SS is a 19-item, self-administered questionnaire designed to measure the perceived availability of functional social support. Scores are transformed to a 0-100 scale, where higher scores mean more available support
Time frame: Baseline, Month 3, Month 6
TEAM vs WL Number of Stroke Risk Medications
The measure represents the number of medications a participant was taken to lower their risk of having another stroke
Time frame: Baseline, Month 3, Month 6
TEAM vs. WL Tablet Routine Questionnaire (TRQ)
The TRQ item is a subject report of the percentage of prescribed medications due reduce stroke risk not taken within the past week.
Time frame: Baseline, Month 3, Month 6
| Milestone | Intervention | Waitlist | Peer Educators | Peer Educator Care Partner |
|---|---|---|---|---|
| Started | 78 | 82 | 7 | 4 |
| Completed | 67 | 66 | 5 | 4 |
| Not completed | 11 | 16 | 2 | 0 |
BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.
| mmHg | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 136.17 ± 1.17 | 136.06 ± 2.34 | 136.28 ± 2.22 | — | — |
| Month 3 | 135.04 ± 1.95 | 137.15 ± 2.8 | 132.93 ± 2.71 | — | — |
| Month 6 | 133.58 ± 1.77 | 133.71 ± 2.55 | 133.44 ± 2.45 | — | — |
BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.
| mmHg | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 82.48 ± 1.10 | 82.61 ± 1.59 | 82.35 ± 1.51 | — | — |
| Month 3 | 80.51 ± 1.10 | 81.56 ± 1.58 | 79.46 ± 1.53 | — | — |
| Month 6 | 81.19 ± 1.06 | 81.10 ± 1.53 | 81.27 ± 1.47 | — | — |
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| mg/dL | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 146.83 ± 7.34 | 151.19 ± 9.82 | 142.48 ± 10.92 | — | — |
| Month 6 | 144.53 ± 5.72 | 148.92 ± 7.65 | 140.14 ± 8.51 | — | — |
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| mg/dL | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 45.68 ± 1.86 | 42.62 ± 2.52 | 48.75 ± 2.74 | — | — |
| Month 6 | 46.14 ± 1.87 | 44.51 ± 2.53 | 47.76 ± 2.75 | — | — |
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| mg/dL | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 80.64 ± 5.84 | 82.88 ± 8.08 | 78.41 ± 8.44 | — | — |
| Month 6 | 80.86 ± 4.46 | 83.08 ± 6.18 | 78.64 ± 6.45 | — | — |
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| mg/dL | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 118.17 ± 15.04 | 132.04 ± 20.05 | 104.3 ± 22.42 | — | — |
| Month 6 | 113.25 ± 16.19 | 137.8 ± 21.58 | 88.70 ± 24.13 | — | — |
Height was measured at baseline and weight was measured at baseline and at 6-month follow-up timepoints. If individuals were unable to provide accurate height and weight measurements, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| kg/m² | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 30.58 ± 0.74 | 31.82 ± 1.02 | 29.34 ± 1.06 | — | — |
| Month 6 | 30.19 ± 0.75 | 31.48 ± 1.05 | 28.89 ± 1.09 | — | — |
Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.
| percentage of glycosylated hemoglobin | Total Participants | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|---|
| Baseline | 7.63 ± 0.18 | 7.93 ± 0.27 | 7.34 ± 0.25 | — | — |
| Month 6 | 7.31 ± 0.22 | 7.24 ± 0.32 | 7.40 ± 0.30 | — | — |
The SKT is a 20-item multiple-choice test designed to measure knowledge and understanding of stroke, stroke risk, stroke risk factors, and stroke prevention practices. In this study, only five specific questions were asked to examine each participant's knowledge of specific stroke risk factors and stroke prevention practices. Possible scores range for 0-5, with a higher score indicating a higher amount of knowledge and understanding
| units on a scale | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners |
|---|---|---|---|---|
| Baseline | 3.98 ± 0.18 | 4.35 ± 0.18 | — | — |
| Month 3 | 4.50 ± 0.18 | 4.28 ± 0.19 | — | — |
| Month 6 | 4.32 ± 0.15 | 4.67 ± 0.15 | — | — |
The GSE a 10-item psychological questionnaire designed to measure an individual's optimistic self-belief in their ability to handle difficult demands, cope with stress, and overcome obstacles. Total scores range from 10 to 40, where higher scores mean a stronger general sense of self-efficacy
| units on a scale | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| Baseline | 34.02 ± 0.78 | 32.72 ± 0.78 | — | — |
| Month 3 | 32.37 ± 0.99 | 32.66 ± 1.00 | — | — |
| Month 6 | 32.13 ± 1.00 | 32.67 ± 0.99 | — | — |
The MOS-SS is a 19-item, self-administered questionnaire designed to measure the perceived availability of functional social support. Scores are transformed to a 0-100 scale, where higher scores mean more available support
| units on a scale | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| Baseline | 72.00 ± 4.69 | 73.40 ± 4.55 | — | — |
| Month 3 | 67.82 ± 5.43 | 68.50 ± 5.43 | — | — |
| Month 6 | 67.70 ± 5.37 | 66.52 ± 5.28 | — | — |
The measure represents the number of medications a participant was taken to lower their risk of having another stroke
| number of medications | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| Baseline | 3.02 ± 0.34 | 2.63 ± 0.35 | — | — |
| Month 3 | 2.75 ± 0.35 | 3.2 ± 0.37 | — | — |
| Month 6 | 2.74 ± 0.33 | 2.71 ± 0.35 | — | — |
The TRQ item is a subject report of the percentage of prescribed medications due reduce stroke risk not taken within the past week.
| percentage of doses missed | Intervention | Waitlist | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| Baseline | 4.7 ± 3.45 | 13.76 ± 3.33 | — | — |
| Month 3 | 6.00 ± 3.72 | 13.70 ± 3.56 | — | — |
| Month 6 | 5.82 ± 3.99 | 11.63 ± 3.81 | — | — |
Collected over From enrollment until end of follow-up, up to 12 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention | 0/160 (0%) | 4/160 (2.5%) | 2/160 (1.3%) |
| Observation | 0/160 (0%) | 14/160 (8.8%) | 10/160 (6.3%) |
| Peer Educators | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Peer Educator Care Partners | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | Intervention | Observation | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| Hospitalization due to underlying medical conditionsGeneral disorders | 4/160 | 12/160 | 0/7 | 0/4 |
| Hospitalization due to unknown reasonsGeneral disorders | 0/160 | 4/160 | 0/7 | 0/4 |
| Hospitalization due to combined medical and psychological conditionsGeneral disorders | 0/160 | 2/160 | 0/7 | 0/4 |
| Hospitalization due to psychological conditions (psychiatric or substance use problems)Psychiatric disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Event | Intervention | Observation | Peer Educators | Peer Educator Care Partners |
|---|---|---|---|---|
| FallGeneral disorders | 2/160 | 0/160 | 0/7 | 0/4 |
| Leg injuryGeneral disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Alcohol intoxicationPsychiatric disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Abdominal painGeneral disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Eye PainEye disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Toe painGeneral disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Drug overdosePsychiatric disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| HematomaVascular disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| High Blood PressureCardiac disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| EnteritisGeneral disorders | 0/160 | 1/160 | 0/7 | 0/4 |
| Age, Continuous(Years) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Mean | 61.3 ± 9.2 | 61.1 ± 9.8 | 59.6 ± 15.1 | 44.5 ± 20.5 | 61.2 ± 14.0 |
| Sex: Female, Male(Participants) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 4 | 4 |
| Male | 78 | 82 | 7 | 0 | 167 |
| Race (NIH/OMB)(Participants) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | — | 0 |
| Asian | 0 | 0 | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | 0 |
| Black or African American | 78 | 82 | 7 | — | 167 |
| White | 0 | 0 | 0 | — | 0 |
| More than one race | 0 | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | — | 0 |
| Lives Alone(participants) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Number | 26 | 29 | 2 | — | 57 |
| Education(years) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Mean | 14.2 ± 2.3 | 13.8 ± 2.1 | — | — | 14.0 ± 2.2 |
| Average systolic blood pressure(mmHg) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Mean | 135.7 ± 18.4 | 135.0 ± 17.5 | — | — | 135.3 ± 17.9 |
| Average diastolic blood pressure(mmHg) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Mean | 83.6 ± 10.7 | 82.4 ± 13.1 | — | — | 83.0 ± 12.0 |
| BMI(kg/m²) | Intervention | Waitlist | Peer Educator | Peer Educator Care Partners | Total |
|---|---|---|---|---|---|
| Mean | 31.0 ± 6.9 | 29.1 ± 5.3 | — | — | 30.1 ± 6.2 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Sep 2025, 64 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 64 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Case Western Reserve University →